Cellular Therapies for Multiple Myeloma: Engineering Hope
Cancers · 19.11.2024 · 16 (22) · 3867
DOI: 10.3390/cancers16223867 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 19.11.2024. Verfasst von Sarah Vera-Cruz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Medizinische Klinik und Poliklinik II und Lehrstuhl für Zelluläre Immuntherapie, Medizinische Klinik II, Universitätsklinikum Würzburg, 97080 Würzbur…. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 156 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Interdisciplinary Center for Clinical Research (IZKF), German Ministry for Science and Education (BMBF, Bundesministerium für Bildung und Forschung, European Union's innovation programme (CARAMBA).
Abstract (Originalsprache)
Multiple myeloma (MM) treatment remains challenging due to its relapsed/refractory disease course as well as intra- and inter-patient heterogeneity. Cellular immunotherapies, especially chimeric antigen receptor (CAR)-T cells targeting B cell maturation antigen (BCMA), mark a major breakthrough, achieving long-lasting remissions and instilling hope for a potential cure. While ongoing clinical trials are increasingly driving approved cellular products towards earlier lines of therapy, novel targets as well as advanced approaches employing natural killer (NK) cells or dendritic cell (DC) vaccines are currently under investigation. Treatment resistance, driven by tumor-intrinsic factors such as antigen escape and the intricate dynamics of the tumor microenvironment (TME), along with emerging side effects such as movement and neurocognitive treatment-emergent adverse events (MNTs), are the major limitations of approved cellular therapies. To improve efficacy and overcome resistance, cutting-edge research is exploring strategies to target the microenvironment as well as synergistic combinatorial approaches. Recent advances in CAR-T cell production involve shortened manufacturing protocols and “off-the-shelf” CAR-T cells, aiming at decreasing socioeconomic barriers and thereby increasing patient access to this potential lifesaving therapy. In this review, we provide an extensive overview of the evolving field of cellular therapies for MM, underlining the potential to achieve long-lasting responses.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medizinische Klinik und Poliklinik II und Lehrstuhl für Zelluläre Immuntherapie, Medizinische Klinik II, Universitätsklinikum Würzburg, 97080 Würzburg, Germany.
- Fraunhofer-Institut für Zelltherapie und Immunologie (IZI), Außenstelle Zelluläre Immuntherapie, 97080 Würzburg, Germany.
- Mildred Scheel Early Career Center, Universitätsklinikum Würzburg, 97080 Würzburg, Germany.
- Interdisziplinäres Zentrum für Klinische Forschung (IZKF), Universitätsklinikum Würzburg, 97080 Würzburg, Germany.
ORCID-Profile: Sarah Vera-Cruz, Maria Jornet Culubret, Verena Konetzki, Sabrina R Friedel, Michael Hudecek, Hermann Einsele, Lukas Scheller
Förderung
- Interdisciplinary Center for Clinical Research (IZKF)
- German Ministry for Science and Education (BMBF, Bundesministerium für Bildung und Forschung
- European Union's innovation programme (CARAMBA)
- Innovative Medicines Initiative 2 Joint Undertaking (ImSAVAR)
- Mildred Scheel Early Career Cancer Center
- Paula and Rodger Riney Foundation Translational Research Award
- German Jose Carreras Leukemia Foundation
- DKMS John Hansen Research Grant
Zitieren
APA
Vera-Cruz, S., Jornet Culubret, M., Konetzki, V., Alb, M., Friedel, S. R., Hudecek, M., Einsele, H., Danhof, S., & Scheller, L. (2024). Cellular Therapies for Multiple Myeloma: Engineering Hope. Cancers, 16(22), 3867. https://doi.org/10.3390/cancers16223867
Vancouver
Vera-Cruz S, Jornet Culubret M, Konetzki V, Alb M, Friedel SR, Hudecek M, et al. Cellular Therapies for Multiple Myeloma: Engineering Hope. Cancers. 2024;16(22):3867. doi:10.3390/cancers16223867
BibTeX
@article{VeraCruz2024,
author = {Vera-Cruz, Sarah and Jornet Culubret, Maria and Konetzki, Verena and Alb, Miriam and Friedel, Sabrina R and Hudecek, Michael and Einsele, Hermann and Danhof, Sophia and Scheller, Lukas},
title = {Cellular Therapies for Multiple Myeloma: Engineering Hope},
journal = {Cancers},
year = {2024},
volume = {16},
number = {22},
pages = {3867},
doi = {10.3390/cancers16223867}
}
EUVIMED